Scripps Clinical Hematology and Oncology 2026

Description

+ Include: 42 videos + 42 file sub vtt + 31 pdfs, size: 23 GB

+ Target Audience: hematologists, medical oncologists, and advanced practice providers

+ Sample video: contact me for sample video

+ Information:

1. Overview

Scripps Cancer Center’s Clinical Hematology and Oncology course is tailored for hematologists, oncologists, surgeons, radiation oncologists, internists, and other health care professionals seeking updates in these specialized areas. The course’s primary objective is to unite clinicians and leading experts across various fields of hematology and oncology in a collaborative and engaging environment to explore the latest clinical advancements and significant breakthroughs. This nationally accredited annual continuing medical education program stands as one of the largest hematology/oncology conferences in the Western United States, alongside other prominent meetings such as ASH, ASCO, and the San Antonio Breast Cancer Symposium. Notably, this conference is among the few that seamlessly integrates topics from both hematology and oncology, offering a unique and comprehensive educational experience.

Course Date: 2026

2. Learning Objectives

1. Explain the clinical and molecular aspects of pathogenesis, diagnostic methods, and treatment options for a range of hematologic disorders.
2. Identify and implement evolving approaches to hematologic malignancies, with a focus on evidence-based standards of care and advancements in diagnosis and treatment.
3. Evaluate and select emerging therapeutic options for managing common malignancies, while considering their appropriate indications and contraindications.
4. Incorporate evolving approaches to solid tumors and breast cancer from a diagnostic, prognostic, and therapeutic perspective.
5. Utilize practical insights from the clinical scenarios presented during panel discussions, focusing on evidence-based approaches to managing patients with common yet serious hematology and oncology conditions.

3. Target Audience

Best for hematologists, medical oncologists, and advanced practice providers who want updates on targeted therapies, immunotherapies, and cancer care.

4. Topics

1. 01 Platelet-Activating Anti-PF4 Disorders

2. 02 ITP 2026 Update

3. 03 Transfusion Medicine for the Practicing Hem-Onc Physician

4. 04 Panel DiscussionQ&A

5. 05 Unusual Thromboses

6. 06 Anticoagulants and Antiplatelet Agents When to Combine and When not to

7. 07 VTE and Anticoagulation 2026 Update

8. 08 Panel DiscussionQ&A

9. 09 Breakout 1 Interesting Cases in Thrombosis

10. 10 Breakout 2 Interesting Cases in Platelet Disorders

11. 11 Breakout 3 Interesting Cases in Bleeding

12. 12 Breakout 4 Interesting Cases in Plasma Cell Dyscrasias

13. 13 Melanoma From Neo-Adjuvant Therapy to Refractory Disease Immune Therapy, Novel Agents, and Managing irAEs – Janice Mehnert, MD

14. 13 Melanoma From Neo-Adjuvant Therapy to Refractory Disease Immune Therapy, Novel Agents, and Managing irAEs – Ryan Sullivan, MD

15. 13 Melanoma From Neo-Adjuvant Therapy to Refractory Disease Immune Therapy, Novel Agents, and Managing irAEs -Allison Betof-Warner, MD, PhD

16. 14 Panel DiscussionQ&A

17. 15 Menin Inhibitors and Other New Targeted Therapies in AML

18. 16 Hypomethylating Agents and Beyond Cutting-Edge Approaches to MDS

19. 17 After IMiDs, Proteosome Inhibitors, and CD38 Antibodies Novel Approaches to RelapsedRefractory Multiple Myeloma

20. 18 Panel DiscussionQ&A

21. 19 Newer Therapeutic Options for Refractory or Relapsed Large Cell Lymphoma

22. 20 Non-Chemotherapy Approaches to Mantle Cell Lymphoma

23. 21 Progress in the Treatment of AL Amyloidosis

24. 22 Panel DiscussionQ&A

25. 23 Beyond BRCA Managing Risk in Women with Moderate-Penetrance Gene Mutations

26. 24 Advances in the Treatment of Metastatic Triple-Negative Breast Cancer

27. 25 Minimal Residual Disease, Disease Monitoring, and Therapy Selection What is the Evidence-Based role for ctDNA in Breast Cancer Therapy

28. 26 Panel DiscussionQ&A

29. 27 Neo-Adjuvant Chemo-Immunotherapy in Resectable NSCLC A New Standard of Care

30. 28 Therapy Beyond First-Line Therapy in EGFR Mutated NSCLC

31. 29 Comparing the Harms and Benefits of Chemo-Immunotherapy or Immunotherapy Alone in the Metastatic Setting

32. 30 Panel DiscussionQ&A

33. 31 Checkpoint Immune Therapy in the Curative Settings of GI Cancers

34. 32 Are TTFs and Novel Small Molecules Moving the Needle in Pancreatic Cancer

35. 33 Panel DiscussionQ&A

36. 34 De-Escalation Strategies in HPV Positive Head and Neck Cancer

37. 35 Cervical Cancer Updates

38. 36 Molecular Classification and Treatment Opportunities in Brain Tumors

39. 37 Panel DiscussionQ&A

40. 38 Optimizing Bone Health in Cancer Care During and After Treatment

41. 39 Management of Common Skin Related Side Effects During and After Cancer Treatment

42. 40 Panel DiscussionQ&A